PARP inhibitors

[Cancer Research] Using a combination of in vivo and in vitro analyses in a novel PyMT-E2A conditional knockout mouse model and derived primary tumor cell lines, researchers reported an essential role of E2A in stemness, metastasis, and therapeutic resistance in breast cancer.

[Oncogene] Investigators provided evidence that the CSC-related transcription factor Oct4 contributes to head and neck squamous cell carcinoma radioresistance by regulating DNA damage response and the CSC phenotype.

[Genes & Development] Scientists review the current understanding of the molecular mechanisms underlying DNA damage-triggered immune responses, including cytosolic DNA sensing via the cGAS/STING pathway.

[Nature Reviews Urology] Ongoing research to establish predictive biomarkers for the treatment of tumors with resistance to second-generation androgen receptor antagonists led to the approval of the PARP inhibitors olaparib and rucaparib in pre-treated metastatic castration-resistant prostate cancer.

[Clinical Epigenetics] The combination of MS023, a type I protein arginine methyltransferases (PRMT) inhibitor, and the PARP inhibitor BMN-673 demonstrated strong synergistic interaction at low nanomolar concentrations in methylthioadenosine phosphorylase-negative NSCLC cell lines A549, SK-LU-1 and HCC4006.

[Journal of Human Genetics] The authors investigated the possibility to predict BRCA1 promoter methylation status based on the morphological and immunohistochemical features of TNBCs.